Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRODIGE 51 - GASTFOX
2024-515221-29-00Phase 3Completed
- Sponsor
- Fédération Francophone de Cancérologie Digestive
- Start
- Jul 2024
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of docetaxel, oxaliplatin, fluorouracil and levoleucovorin in gastroesophageal adenocarcinoma (2 arms), sponsored by Fédération Francophone de Cancérologie Digestive. Primary endpoint: Progression-free survival at 12 months. Started Jul 2024; status: completed.
02
Drugs
docetaxeloxaliplatinfluorouracillevoleucovorin
03
Conditions
gastroesophageal adenocarcinoma
Beyond the preview
Go deeper on 2024-515221-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515221-29-00.